In the DRCR Protocol T trial comparing intravitreal bevacizumab, ranibizumab, and aflibercept for center-involving diabetic macular edema, which finding was reported?
- A All three agents produced identical visual outcomes at every level of baseline acuity
- B Bevacizumab was superior to both other agents at all baseline acuities
- C Aflibercept was superior when baseline visual acuity was worse than 20/50, with no significant difference among agents at better baseline acuity ✓
- D Laser photocoagulation remained superior to all three anti-VEGF agents
Correct answer: C. Aflibercept was superior when baseline visual acuity was worse than 20/50, with no significant difference among agents at better baseline acuity
Explanation
Protocol T showed that at 1 year, eyes with baseline acuity worse than 20/50 gained more vision with aflibercept than with bevacizumab or ranibizumab, whereas among eyes starting at 20/50 or better there was no statistically significant difference between the three agents. This stratified result guides drug selection based on presenting acuity and is the single most examined fact from this trial.
Reference: Ryan's Retina, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.